Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Privia Health Group, Inc.NASDAQ: PRVA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $3.36M rose 29.9% year over year, behind the +48.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +29.9% toward the trailing-twelve-month pace of +48.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 9.91M USD
- Year-over-year change
- +36.3%
- 4-year CAGR
- +41.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.91M | +36.3% |
| FY2024 | 2024-12-31 | 7.27M | +11.3% |
| FY2023 | 2023-12-31 | 6.53M | +42.9% |
| FY2022 | 2022-12-31 | 4.57M | +85.5% |
| FY2021 | 2021-12-31 | 2.46M | — |
Depreciation & Amortization vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 depreciation & amortization of $12.06M is the 8th largest of the 10 companies compared; the peer median is $34.53M.
- Its year-over-year change of +48.7% is the 2nd highest of 10, against a peer median of +11.8%.
- Depreciation & amortization amounts to 0.5% of revenue for PRVA, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $370.85M | -0.4% | +10.7% | 14.7% | |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Mar 2026 | $50.3M | +18.5% | +1.5% | 16.6% | |
| LTM Mar 2026 | $34.69M | +5.2% | +9.1% | 14.6% | |
| LTM Apr 2026 | $34.53M | +22.9% | +7.5% | 7.0% | |
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $24.21M | -79.4% | +22.2% | 1.3% | |
| LTM Jun 2026 | $12.06M | +48.7% | +29.4% | 0.5% | |
| LTM Mar 2026 | $6.61M | +31.8% | +8.2% | 2.3% | |
| LTM Mar 2026 | $3.65M | -76.2% | +2.8% | 2.9% | |
| Peer median (excluding PRVA) | $34.53M | +11.8% | +9.1% | 2.9% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (190.65M) | (12.06M) | 23.08M | 14.39M | 22.92M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| Deferred Income Tax | (28.41M) | (7M) | 7.47M | 8.82M | 10.87M |
| Stock-Based Compensation | 253.53M | 67.36M | 0 | 0 | 0 |
| Change in Working Capital | 17.97M | (6.35M) | 8.66M | 19.47M | 44.29M |
| Accounts Receivables | (14.64M) | (72.2M) | (96.88M) | (19.82M) | (36.67M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.85M | 118.36M | 52.85M | 14.82M |
| Other Working Capital | 32.61M | 59M | (12.82M) | (13.55M) | 66.14M |
| Other Non-Cash Items | 157K | 687K | 35.05M | 59.34M | 75.42M |
| Operating Cash Flow | 55.06M | 47.2M | 80.79M | 109.28M | 163.4M |
| Capital Expenditures | (547K) | (104K) | (113K) | (5.02M) | (1.2M) |
| Acquisitions (Net) | (32.23M) | 125K | (47.89M) | (5.3M) | (181.72M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (125K) | 0 | 0 | 1.35M |
| Investing Cash Flow | (32.78M) | (104K) | (48.01M) | (10.33M) | (181.57M) |
| Debt Repayment | (875K) | (33.25M) | 0 | 0 | (2.46M) |
| Common Stock Issued | 223.69M | 13.45M | 8.74M | 2.68M | 8.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.15M) | 125K | 0 | 0 | 1.11M |
| Financing Cash Flow | 213.66M | (19.68M) | 8.74M | 2.68M | 6.7M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 235.94M | 27.42M | 41.52M | 101.64M | (11.46M) |
| Free Cash Flow | 54.51M | 47.09M | 80.67M | 104.26M | 162.2M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.